India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
You may also be interested in...
Indian Court Hands Novartis Setback In Gleevec Patent Case
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.
Abbott To File In Thailand For Kaletra Pediatric AIDS Indication
Action marks a change in firm’s commercialization policy toward the Southeast Asian nation.
GSK Jumps Into Growing China R&D Space
Shanghai-based center will focus on Alzheimer’s, multiple sclerosis and Parkinson’s.